Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients

Fig. 1

Immunohistochemistry showed the location of CD133 expression in the TU and AN of HCC patients. a A representative low C and low N CD133 immunostaining of HCC using the CD133 antibody (100 x). b A representative high C and low N CD133 immunostaining of HCC using the CD133 antibody (100 X). c A representative low C and high N CD133 immunostaining of HCC using the CD133 antibody (100 X). d A representative high C and high N CD133 immunostaining of HCC using the CD133 antibody (100 X). e A representative low C and low N CD133 immunostaining of AN using the CD133 antibody (100 X). f A representative high C and low N CD133 immunostaining of AN using the CD133 antibody (100 X). g The mean of the cytoplasmic CD133 scores was calculated in the TU and pair-matched AN, and the cytoplasmic CD133 scores were compared in the TU and pair-matched AN. h The mean of the nuclear CD133 scores was calculated in the TU and pair-matched AN, and the nuclear CD133 scores were compared in the TU and pair-matched AN. C: cytoplasm. N: nucleus. TU: tumor. AN: adjacent normal liver tissue. The corresponding isotype control of the CD133 antibody was obtained using normal rabbit IgG

Back to article page